Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 35


Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Chen YB, Efebera YA, Johnston L, Ball ED, Avigan D, Lekakis LJ, Bachier CR, Martin P, Duramad O, Ishii Y, Han S, Jung YJ, Lee D, Kunkel L, Negrin RS, Bui JD.

Biol Blood Marrow Transplant. 2017 Jan 16. pii: S1083-8791(17)30194-5. doi: 10.1016/j.bbmt.2017.01.069. [Epub ahead of print]


Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.

Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1921-5. doi: 10.1016/j.bbmt.2015.05.024.


Treatment of Acquired von Willebrand Syndrome and Prevention of Bleeding Postautologous Stem Cell Transplant during Severe Pancytopenia with IVIG.

Zoghi B, Shaughnessy P, Lyons RM, Helmer R 3rd, Bachier C, LeMaistre CF.

Case Rep Hematol. 2015;2015:809313. doi: 10.1155/2015/809313.


Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial.

Maziarz RT, Devos T, Bachier CR, Goldstein SC, Leis JF, Devine SM, Meyers G, Gajewski JL, Maertens J, Deans RJ, Van't Hof W, Lazarus HM.

Biol Blood Marrow Transplant. 2015 Apr;21(4):720-8. doi: 10.1016/j.bbmt.2014.12.025.


Association between takotsubo cardiomyopathy and axitinib: case report and review of the literature.

Ovadia D, Esquenazi Y, Bucay M, Bachier CR.

J Clin Oncol. 2015 Jan 1;33(1):e1-3. doi: 10.1200/JCO.2013.48.7280. Review. No abstract available.


High white blood cell concentration in the peripheral blood stem cell product can induce seizures during infusion of autologous peripheral blood stem cells.

Bachier C, Potter J, Potter G, Sugay R, Shaughnessy P, Chan K, Jude V, Madden R, LeMaistre CF.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1055-60. doi: 10.1016/j.bbmt.2011.12.500.


Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV; Blood and Marrow Transplant Clinical Trials Network..

Blood. 2011 Jul 14;118(2):282-8. doi: 10.1182/blood-2011-03-344853.


Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.

Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M; Maribavir 1263-300 Clinical Study Group..

Lancet Infect Dis. 2011 Apr;11(4):284-92. doi: 10.1016/S1473-3099(11)70024-X. Erratum in: Lancet Infect Dis. 2011 May;11(5):343.


Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.

LeMaistre JA, Bachier C, Smith B, LeMaistre CF, Shaughnessy PJ.

J Oncol Pharm Pract. 2012 Mar;18(1):17-22. doi: 10.1177/1078155210392616.


Graft-versus-host disease treatment: predictors of survival.

Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolaños-Meade J, Weisdorf D; Blood and Marrow Transplant Clinical Trials Network..

Biol Blood Marrow Transplant. 2010 Dec;16(12):1693-9. doi: 10.1016/j.bbmt.2010.05.019.


Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.

Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, Shpall EJ, Macmillan ML, Soiffer RJ.

Biol Blood Marrow Transplant. 2009 Jul;15(7):777-84. doi: 10.1016/j.bbmt.2009.03.012. Review.


Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease.

Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Callander NS, Essell JH, Flomenberg N, Selby G, Lemaistre CF.

Biol Blood Marrow Transplant. 2005 Mar;11(3):188-93.


Phase II study of a moderate-intensity preparative regimen with allogeneic peripheral blood stem cell transplantation for hematologic diseases: the Texas Transplant Consortium experience.

Shaughnessy PJ, Ornstein D, Ririe D, Callander N, Anderson JE, Pollack MS, Freytes CO, Cruz J, Rodriquez T, Bachier C, LeMaistre CF.

Biol Blood Marrow Transplant. 2002;8(8):420-8.


A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation.

Pecora AL, Stiff P, LeMaistre CF, Bayer R, Bachier C, Goldberg SL, Parthasarathy M, Jennis AA, Smith AK, Douville J, Chen B, Armstrong RD, Mandalam RK, Preti R.

Bone Marrow Transplant. 2001 Aug;28(3):295-303.


Infusional vinorelbine in relapsed or refractory lymphomas.

Sarris AH, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Bachier C, Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F.

Leuk Lymphoma. 2000 Oct;39(3-4):291-9.


Ig heavy chain CDR3 size diversities are similar after conventional peripheral blood and ex vivo expanded hematopoietic cell transplants.

Gokmen E, Bachier C, Raaphorst FM, Muller T, Armstrong D, LeMaistre CF, Teale JM.

Bone Marrow Transplant. 2001 Feb;27(4):413-24.


Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue.

Shaughnessy PJ, Ririe DW, Ornstein DL, Kissack B, Bickford DJ, Molina R, Lanzkron S, Bachier C, Nanez A, LeMaistre CF.

Bone Marrow Transplant. 2001 Jan;27(2):221-4.

Items per page

Supplemental Content

Loading ...
Support Center